{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:58Z","timestamp":1791979138938,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jgar.2018.05.017","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T13:06:22Z","timestamp":1527599182000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Activity of imipenem\/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015\u20132016"],"prefix":"10.1016","volume":"15","author":[{"given":"Sibylle H.","family":"Lob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary R.","family":"Motyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.05.017_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2110-5820-1-47","article-title":"The rising problem of antimicrobial resistance in the intensive care unit","volume":"1","author":"Brusselaers","year":"2011","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jgar.2018.05.017_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.diagmicrobio.2013.11.025","article-title":"Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009\u20132011)","volume":"78","author":"Sader","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.05.017_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijantimicag.2015.02.022","article-title":"Ceftazidime\/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia","volume":"46","author":"Sader","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.05.017_bib0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jgar.2015.05.005","article-title":"Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011\u20132013","volume":"3","author":"Lob","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2018.05.017_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/0885066615619895","article-title":"Antimicrobial resistance in the intensive care unit: a focus on Gram-negative bacterial infections","volume":"32","author":"MacVane","year":"2017","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jgar.2018.05.017_bib0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhin.2009.02.021","article-title":"Extended-spectrum \u03b2-lactamase-producing organisms","volume":"73","author":"Falagas","year":"2009","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jgar.2018.05.017_bib0035","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1128\/AAC.01020-07","article-title":"Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality","volume":"52","author":"Schwaber","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.05.017_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.diagmicrobio.2017.06.009","article-title":"Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: prevalence and risk factors","volume":"89","author":"Trinh","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.05.017_bib0045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijantimicag.2010.08.005","article-title":"In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy","volume":"36","author":"Riou","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.05.017_bib0050","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01169-07","article-title":"ReAct\u2013Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli","volume":"52","author":"Giske","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2018.05.017_bib0055","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/590061","article-title":"Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front","volume":"47","author":"Kollef","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.05.017_bib0060","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/AAC.00607-13","article-title":"Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae","volume":"57","author":"McLaughlin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.05.017_bib0065","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00310-16","article-title":"Global assessment of the activity of tigecycline against multidrug-resistant Gram-negative pathogensbetween 2004 and 2014 as part of the tigecycline evaluation and surveillance trial","volume":"2","author":"Giammanco","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.jgar.2018.05.017_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jgar.2013.03.010","article-title":"Global antibacterial resistance: the never-ending story","volume":"1","author":"Theuretzbacher","year":"2013","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2018.05.017_bib0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2014.07.005","article-title":"Ceftazidime\u2013avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)","volume":"80","author":"Flamm","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.05.017_bib0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijantimicag.2012.10.014","article-title":"Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002\u20132010","volume":"41","author":"Hawser","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.05.017_bib0085","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.05.017_bib0090","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/AAC.36.9.2046","article-title":"Interplay of impermeability and chromosomal \u03b2-lactamase activity in imipenem-resistant Pseudomonas aeruginosa","volume":"36","author":"Livermore","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.05.017_bib0095","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro activity of imipenem\u2013relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.05.017_bib0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2017.02.018","article-title":"In vitro activity of imipenem\u2013relebactam against Gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015\u2014results from the SMART global surveillance program","volume":"88","author":"Lob","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.05.017_bib0105","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against Gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.05.017_bib0110","unstructured":"National Institutes of Health. US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/results?term=MK-7655&Search=Search [Accessed 15 January 2018]."},{"key":"10.1016\/j.jgar.2018.05.017_bib0115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijantimicag.2016.01.015","article-title":"Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii","volume":"47","author":"Lob","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.05.017_bib0120","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 27th ed. CLSI supplement M100, 27th ed. Wayne, PA: CLSI. 2017."},{"key":"10.1016\/j.jgar.2018.05.017_bib0125","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition. Document M07-A10. Wayne, PA: CLSI. 2015."},{"key":"10.1016\/j.jgar.2018.05.017_bib0130","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. EUCAST 2017. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.1_Breakpoint_Tables.pdf [Accessed 15 January 2018]."},{"key":"10.1016\/j.jgar.2018.05.017_bib0135","first-page":"1690","article-title":"Imipenem-resistance in Serratia marcescens is mediated by plasmid expression of KPC-2","volume":"21","author":"Su","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jgar.2018.05.017_bib0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jac\/dki166","article-title":"Emergence of Enterobacteriaceae producing extended-spectrum \u03b2-lactamases (ESBLs) in the community","volume":"56","author":"Pitout","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.05.017_bib0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/138161213804070348","article-title":"Enterobacteriaceae that produce extended-spectrum \u03b2-lactamases and AmpC \u03b2-lactamases in the community: the tip of the iceberg?","volume":"19","author":"Pitout","year":"2013","journal-title":"Curr Pharm Des"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518301012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518301012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T12:29:40Z","timestamp":1544099380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716518301012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":29,"alternative-id":["S2213716518301012"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.05.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of imipenem\/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015\u20132016","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}